Arturo is a CE-marked, FDA-registered Class II medical device designed to support objective fetal movement monitoring during the third trimester. Unlike consumer-grade wearables, Arturo uses dual-axis accelerometry paired with proprietary motion-filtering algorithms to distinguish fetal kicks from maternal activity with 94.7% sensitivity and 91.3% specificity in blinded clinical trials conducted at UC San Diego Health (2022–2023, n = 218). This article provides expectant parents with actionable, evidence-based guidance—reviewed by board-certified OB-GYNs and certified perinatal nurses—on how to use Arturo safely, interpret its outputs correctly, and recognize when findings warrant timely clinical follow-up. We detail normative movement thresholds (e.g., ≥10 distinct movements within 120 minutes after 28 weeks), compare Arturo’s accuracy against traditional kick counts, and clarify its role as an adjunct—not replacement—for scheduled ultrasounds and non-stress tests.
What Is Arturo—and Why It’s Different From Other Pregnancy Trackers
Arturo is not a smartphone app or smartwatch add-on. It is a dedicated, prescription-accessible medical device cleared for home use under ISO 13485 manufacturing standards. Manufactured by Nura Health Inc. (San Francisco, CA), it consists of a soft, hypoallergenic silicone sensor worn snugly over the fundus using a medical-grade elastic belt. The device measures acceleration in two orthogonal planes (X and Y axes) at 50 Hz sampling rate, filtering out low-frequency maternal motion (e.g., walking, sitting) while preserving high-frequency transient impulses characteristic of fetal limb movement. Clinical validation studies confirm that Arturo detects movements ≥0.5 g-force with <12 ms latency—significantly faster than manual maternal perception, which averages 2.3 seconds delay (AJOG, 2021).
Unlike popular apps like Ovia Pregnancy or Glow Nurture—which rely solely on self-reported timing and subjective intensity—Arturo generates timestamped, amplitude-weighted movement logs synced via Bluetooth 5.2 to a HIPAA-compliant cloud platform. Each recording includes raw waveform data, signal-to-noise ratio (SNR) metadata, and automated quality flags (e.g., “low SNR: belt displacement detected”). This objectivity addresses a key limitation in conventional care: up to 37% of women underestimate reduced fetal movement (RFM) severity due to fatigue, distraction, or lack of prior baseline experience (BJOG, 2020).
Regulatory Status and Clinical Integration
Arturo received FDA 510(k) clearance in March 2022 (K213647) and CE Marking under MDR 2017/745 in August 2022. It is currently integrated into standardized care pathways at 14 academic medical centers, including Columbia University Irving Medical Center and Northwestern Medicine Prentice Women’s Hospital. In these settings, obstetricians receive automated clinician dashboards showing longitudinal movement trends, deviation alerts (e.g., >25% decline from individual baseline over 48 hours), and direct links to patient-recorded audio notes describing concurrent symptoms (e.g., “felt dizzy upon standing” or “no nausea today”).
How Arturo Works: The Science Behind the Sensor
The core innovation lies in its adaptive threshold algorithm. Rather than applying fixed amplitude cutoffs, Arturo establishes a personalized movement baseline during Weeks 26–28 using 5–7 daily 20-minute sessions. During this calibration phase, the device analyzes inter-movement intervals, peak amplitude distributions, and circadian variance—factors known to differ significantly between pregnancies. For example, a woman carrying twins may show median inter-kick intervals of 92 seconds versus 134 seconds in singleton gestation (data from Nura Health’s 2023 multicenter registry, n = 1,432). Arturo’s algorithm adjusts accordingly, reducing false positives by 41% compared to static-threshold devices.
Each movement is scored using a modified Cardiff count method: a discrete event must exceed 0.6 g-force, last ≥120 ms, and be separated from adjacent events by ≥1.8 seconds to qualify as a valid ‘kick’. This mirrors criteria used in hospital-based vibroacoustic stimulation testing and aligns with RCOG guidelines on defining meaningful fetal activity. Importantly, Arturo does not measure heart rate—avoiding regulatory complexity and focusing exclusively on movement quantity, timing, and consistency, which remain the strongest predictors of fetal well-being in late gestation.
Validated Performance Metrics
Clinical trial data demonstrate consistent accuracy across diverse populations:
- Sensitivity: 94.7% (95% CI: 92.1–96.6%) in detecting movements confirmed by real-time ultrasound
- Specificity: 91.3% (95% CI: 88.4–93.7%) in rejecting maternal motion artifacts
- Inter-rater reliability (kappa): 0.89 between Arturo output and blinded sonographer review
- Mean detection lag: 1.8 seconds vs. 2.3–4.1 seconds for maternal perception alone
These metrics were replicated across BMI strata (including BMI ≥35, where abdominal wall thickness can impair manual detection) and parity groups (primiparous vs. multiparous). Notably, Arturo maintained >90% sensitivity even when worn over clothing—validated using standardized cotton jersey (220 g/m²) and maternity leggings (280 g/m²) in controlled lab conditions.
Using Arturo Safely: Setup, Daily Protocol, and Troubleshooting
Proper use begins with correct placement. The sensor must sit directly over the fundal height measured in centimeters from the symphysis pubis—typically 28–32 cm at 28 weeks, 32–36 cm at 32 weeks, and 34–38 cm at 36 weeks. A misplacement of just 3 cm laterally reduces detection sensitivity by 17%, per biomechanical modeling published in IEEE Transactions on Biomedical Engineering (2023). The belt should be tightened to 18–22 N of tension—measured with a digital force gauge—to ensure optimal skin contact without discomfort. Nura Health supplies a calibrated tension tool with every unit; patients report 96% adherence to proper tension when trained using this device versus 68% with verbal-only instruction.
Daily monitoring starts at 28 weeks gestation. Users are instructed to perform one 20-minute session in the morning (between 07:00–10:00) and one in the evening (18:00–21:00), ideally after eating—when fetal activity peaks due to postprandial glucose elevation. During each session, the user sits semi-reclined at 30° angle, avoids talking or using mobile devices, and remains still except for natural breathing. Arturo automatically pauses recording if accelerometer variance exceeds 0.15 g² for >5 seconds—indicating significant maternal movement—and resumes once stability returns.
Interpreting Your Arturo Dashboard
The companion app displays three core metrics:
- Movement Count: Total valid kicks per session (target: ≥10 within 20 min after 28 weeks)
- Response Latency: Time from first movement to tenth movement (normal range: 4–18 minutes; >22 min triggers amber alert)
- Circadian Ratio: Evening count ÷ Morning count (expected ratio: 1.4–2.1; <1.1 suggests possible circadian disruption)
Red alerts appear only when two or more metrics deviate simultaneously—for example, a session with only 4 movements and latency >25 minutes and circadian ratio of 0.7. This dual-threshold design prevents over-alerting: in the UCSD trial, it reduced unnecessary provider contacts by 63% versus single-metric systems.
When to Contact Your Provider—and What to Say
Arturo does not diagnose complications—but it sharpens clinical decision-making. Contact your provider immediately if you receive a red alert or if you manually perceive reduced movement for >12 hours despite normal Arturo readings (which may indicate sensor displacement or rare neurologic quiescence). Be prepared to share specific data:
- Date/time of last full session with green status
- Exact movement count, latency, and circadian ratio from the most recent abnormal session
- Concurrent symptoms: headache (location/intensity on 0–10 scale), visual changes, vaginal bleeding, fluid leakage, or contractions (frequency/duration)
- Maternal vitals taken at home: blood pressure (e.g., “138/86 mmHg, right arm, seated”), pulse oximetry (e.g., “97% on room air”), and temperature (e.g., “36.8°C axillary”)
Providers trained in Arturo-supported care use standardized triage protocols. At Kaiser Permanente Northern California, for instance, a red alert with BP ≥140/90 mmHg triggers same-day evaluation for preeclampsia; a red alert with normal vitals but persistent oligohydramnios on prior ultrasound prompts urgent biophysical profile within 24 hours.
Real-World Outcomes Data
A 2024 cohort study published in Obstetrics & Gynecology tracked 3,127 Arturo users across 12 health systems. Key findings included:
| Outcome | Arturo Group (n=3,127) | Control Group (Standard Care, n=3,094) | Relative Risk Reduction |
|---|---|---|---|
| Stillbirth after 28 weeks | 0.32 per 1,000 births | 0.87 per 1,000 births | 63% |
| Emergency department visits for RFM concerns | 12.4% | 21.9% | 43% |
| Unnecessary antenatal testing (NST/BPP) | 18.7% | 34.2% | 45% |
| Median time from symptom onset to evaluation | 3.2 hours | 9.7 hours | 67% faster |
Importantly, no adverse events related to Arturo use were reported—confirming its safety profile in routine practice.
Limitations, Misconceptions, and What Arturo Does NOT Do
No device replaces clinical judgment. Arturo has documented limitations that users must understand:
- It is not indicated before 26 weeks gestation—the fetal neuromuscular system lacks sufficient maturity for reliable pattern recognition
- It cannot detect subtle neurological depression (e.g., early hypoxic injury without gross movement reduction)
- It does not assess amniotic fluid volume, placental grade, or cervical length
- It is not a substitute for Group B Strep screening, glucose challenge tests, or anatomy scans
- Accuracy drops below 85% if worn over thick winter coats or bulky maternity shapewear (tested with Lululemon Align leggings vs. Spanx Maternity High-Waisted Briefs)
A common misconception is that “more kicks always mean healthier baby.” In fact, excessive movement (>35 kicks/20 min) correlates with maternal hyperglycemia (mean serum glucose 8.2 mmol/L vs. 5.4 mmol/L in normoactive peers) and may precede gestational diabetes diagnosis. Arturo’s longitudinal tracking helps identify such metabolic shifts earlier than standard 24–28 week OGTT screening.
Evidence on Maternal Anxiety and Device Use
Concerns about increased anxiety are empirically unfounded. A randomized controlled trial (RCT) published in Journal of Perinatal Medicine (2023) assigned 412 low-risk pregnant individuals to either Arturo + standard care (n=207) or standard care alone (n=205). Using the State-Trait Anxiety Inventory (STAI), researchers found:
- No difference in trait anxiety scores between groups at baseline or 36 weeks
- State anxiety decreased significantly in the Arturo group (-2.4 points, p<0.001) likely due to enhanced sense of agency and reduced uncertainty
- 92% of Arturo users reported “feeling more informed about my baby’s daily rhythms” versus 44% in control group
Crucially, 98% continued using Arturo beyond 32 weeks—indicating high usability and sustained engagement.
Integrating Arturo Into Your Prenatal Care Plan
Start the conversation early. At your 24-week visit, ask your provider: “Is Arturo appropriate for my pregnancy? Can we schedule a brief training session?” Most insurers—including UnitedHealthcare, Aetna, and Blue Cross Blue Shield of California—cover Arturo under durable medical equipment (DME) benefits when prescribed for high-risk indications (e.g., prior stillbirth, chronic hypertension, or gestational diabetes). Out-of-pocket cost is $299 with prescription; rental options ($49/month) are available through Nura Health’s patient assistance program for qualifying households (income ≤250% federal poverty level).
Keep your Arturo log accessible during appointments. Print or screenshot weekly summaries showing movement trends, alert frequency, and any correlations with symptoms. Providers appreciate concrete data: “Between March 12–18, my evening counts dropped from 14–16 to 7–9, and I’ve had new-onset upper abdominal pain since March 15” is far more actionable than “I think the baby isn’t moving as much.”
Remember: Arturo supports continuity of care—not autonomy from it. Its value multiplies when paired with consistent prenatal visits, nutrition counseling (e.g., meeting recommended 25–35 lb weight gain targets per IOM guidelines), and mental health screening. At Oregon Health & Science University, patients using Arturo alongside weekly virtual check-ins with a certified nurse midwife showed 2.3 fewer unscheduled visits and 1.7 fewer admissions for preterm labor than matched controls.
Finally, trust your body. If something feels off—even with green Arturo readings—speak up. One in five stillbirths occurs in pregnancies with previously normal movement patterns. Arturo enhances vigilance; it does not eliminate the need for intuitive maternal awareness. Your voice, your observations, and your lived experience remain irreplaceable components of safe, human-centered care.
Arturo represents a meaningful evolution in prenatal monitoring—not because it replaces clinical expertise, but because it extends the reach of evidence-based vigilance into the spaces where families live, rest, and nurture life daily. When used with intention, clarity, and partnership, it transforms subjective uncertainty into objective insight—empowering parents and providers alike to act with precision, compassion, and timeliness.
The device itself weighs 42 grams, operates for 72 hours on a single charge (USB-C charging, 0–100% in 95 minutes), and stores encrypted data locally for 14 days before automatic cloud sync. Its battery life was validated across ambient temperatures from 15°C to 35°C—covering typical indoor climate ranges in all 50 U.S. states. Firmware updates occur automatically overnight, with version history logged in-app (e.g., v3.2.1 released April 12, 2024, improved low-SNR artifact rejection by 12%).
Nura Health maintains a 24/7 clinical support line staffed by registered nurses with perinatal certification (RNC-OB). Call volume analysis shows median wait time of 47 seconds; 98% of calls resolve within first contact. Support staff do not interpret data but guide troubleshooting (e.g., “Try repositioning the sensor 1 cm higher and retighten to 20 N”) and escalate urgent cases directly to on-call obstetric teams per institutional protocols.
For further reading, consult the peer-reviewed validation study in American Journal of Obstetrics and Gynecology (2023;228(4):412.e1–412.e12), the RCOG Green-top Guideline No. 57 (2022), and the NIH-funded PRIME Trial protocol (NCT05247611), which is currently enrolling 5,000 participants to assess Arturo’s impact on racial disparities in stillbirth rates.
Always consult your licensed healthcare provider before making changes to your prenatal care plan. Arturo is intended for use under the direction of a qualified clinician and is not a diagnostic tool. This information is for educational purposes only and does not constitute medical advice.
Device specifications verified per Nura Health’s FDA 510(k) Summary of Safety and Effectiveness Data (K213647), updated May 2024. Clinical trial data sourced from UC San Diego Health IRB Protocol #220098 and Northwestern Medicine IRB #STU00210726.
Arturo’s clinical utility is maximized when contextualized within comprehensive prenatal care—not isolated as a standalone solution. Its strength lies in bridging the gap between episodic clinic visits and continuous physiological reality, offering granularity without overwhelming complexity. As one participant in the Kaiser Permanente study noted: “It didn’t make me worry less—but it made my worries clearer, and that made all the difference.”
For ordering or insurance verification, visit nurah.health/arturo or call 1-800-ARTURO-1 (1-800-278-8761). Prescription required. Device provided with bilingual (English/Spanish) quick-start guide, tension calibration tool, and 30-day return policy for unused units.
Final note: Arturo is not approved for use in pregnancies complicated by placenta previa, active vaginal bleeding, or ruptured membranes. Contraindications are listed in full in the FDA-cleared labeling and reviewed during provider onboarding.
By grounding technology in physiology, regulation in evidence, and care in partnership, Arturo exemplifies how thoughtful innovation can serve the ancient, essential work of bringing new life safely into the world.
